The Summary

Almost all studies on vaccines and type 1 diabetes have found that vaccination does not increase the risk of type 1 diabetes or autoimmunity.

Researchers are also working to develop a vaccine to prevent or treat type 1 diabetes, e.g., the GAD65 vaccine (Ludvigsson 2017). The rotavirus vaccine may also be able to prevent type 1 diabetes, although the jury is still out.

My boys are fully vaccinated, including to COVID-19, and we all get flu shots every fall. 

The Details

Vaccines and Type 1 Diabetes

Most studies have not found vaccines to be associated with the development of type 1 diabetes or type 1-associated autoantibodies. For example:

On the other hand, a Swedish study found that the HiB (hemophilus influenza B) vaccine may induce type 1-related autoantibodies in 1 year old children (Wahlberg et al. 2003). Another study compared Finnish children who had received the HiB vaccine and those who had not (in the two years prior to the introduction of the vaccine). They found that children receiving 4 doses as compared to those receiving no doses had slightly higher rates of type 1 diabetes, beginning about 3-3.5 years after immunization. Yet HiB vaccination in the first month of life may also be associated with a decreased risk of type 1 diabetes (Classen and Classen 2002).

Does the Rotavirus Vaccine Prevent Type 1?

Vaccines may also be able to prevent type 1: in Australian infants and young children, after the oral rotavirus vaccine was added as a routine vaccines in 2007, type 1 diabetes incidence declined (Perrett et al. 2019a; note that there was an error in the original study so the overall numbers may not be right, but the findings still stand (Perrett et al. 2019b)). The change was only in children aged 4 and younger. In the U.S., there was a 33% decrease in type 1 diabetes incidence in children fully (not partially) vaccinated with the rotavirus vaccine compared to unvaccinated children. There was also a decrease in type 1 diabetes incidence in children aged 0-4 from 2006-2017, following the vaccine introduction in 2006 (Rogers et al. 2019). However, two large studies of U.S. children found no associations between partial or full rotavirus vaccination (Burke et al. 2020; Glanz et al. 2020). In Finland, one study found that the rotavirus vaccine had no effect on type 1 diabetes rates in children (Vaarala et al. 2017), and a placebo-controlled trial found no difference in type 1 diabetes incidence between those receiving this vaccine and those receiving a placebo after 12-14 years of follow-up (Hemming-Harlo et al 2019). However, another study found that decreasing rotavirus infection rates did lead to a lower type 1 diabetes incidence in Finland, so the vaccine did help (Parviainen et al. 2023). In Israel, after the vaccine was used, there was a lower increasing prevalence of type 1 diabetes in children under 5 (Blumenfeld et al. 2021). In Sweden, there was no difference in type 1 onset in relation to the rotavirus vaccine (Rangert et al. 2023).

A systematic review and meta-analysis of these studies found that this vaccine was not associated with type 1 (or celiac disease) overall-- however, it did appear to be protective in children under 5 (Zhang et al. 2022).

For some more discussion on this topic, see Harrison et al. 2019. I expect we will be seeing more follow up on this in other countries.

Celiac Disease

In Finland, the rotavirus vaccine was linked to a lower risk of celiac disease (Hemming-Harlo et al. 2019). In the U.S., the rotavirus vaccine does not appear to be linked to a decreased risk of celiac disease. The risk of celiac did go up over time, but for children born after the vaccine was introduced, the risk between the vaccinated and unvaccinated children did not differ (Kim et al. 2022).

The BCG Vaccine: NOD Mice vs. Humans

The case of the bacillus Calmette-Guerin (BCG) vaccine is interesting, in that it shows how animal studies may not translate well to human studies. The BCG vaccine prevents the development of diabetes in NOD (non-obese diabetic) mice, an animal model of autoimmune diabetes (Harada et al. 1990). In humans, the BCG vaccine sometimes has been shown to preserve beta cell function when given just after diagnosis. On the basis of these studies, a prospective study in Germany examined whether vaccination might prevent beta cell damage in children genetically at risk for type 1 diabetes. The study compared children who received this vaccine before 3 months of age, after 3 months of age, and not at all. It found that the vaccine did not affect the development of type 1 diabetes-related autoantibodies. But, instead of being protective to beta cells, it actually sped up the rate of progression to type 1 in children who had these antibodies. And, the age of diabetes onset was significantly younger in children who had BCG vaccination (2.8 years) than in children who were not vaccinated (5 years). While this study does not suggest that BCG vaccination will increase the overall incidence of type 1 diabetes, it was found to accelerate development of the disease. The mechanism may involve stimulation of the immune system via inflammation (Huppmann et al. 2005). This is an interesting example of a case where something that can prevent diabetes in NOD mice might be able to accelerate type 1 diabetes in humans (see the Of Mice, Dogs, and Men page for more on this point). Large Canadian studies found that the BCG vaccine in early life did not affect the overall risk of childhood type 1 diabetes (Corsenac et al. 2021; Rousseau et al. 2016)

Wait! A newer study from Quebec found that early life BCG vaccination was associated with lower risks of both type 1 and type 2 diabetes from early to middle adulthood, but not of LADA (Corsenac et al. 2022).  And, a recent reanalysis of Swedish data and analysis of Israeli data show that maybe the BCG vaccine was in fact protective against type 1 diabetes, in females anyhow (Klein 2020). And a study from Turkey and Greece found that one dose of the BCG vaccine at age 9 appeared to delay the onset of type 1 diabetes 2.5 years (Doupis et al. 2021). In adults with diabetes, multi-dose BCG therapy was associated with multi-year and stable lowering of HbA1c in those with type 1 diabetes, but not type 2. Also, countries with mandatory neonatal BCG vaccination policies had a lower incidence of type 1 diabetes in two international databases (Dias et al. 2023).

So who knows what is going on. 

The BCG vaccine is also being used by the Faustman lab to aim to reverse type 1 diabetes (Kühtreiber and Faustman 2019; Kühtreiber et al. 2018; Faustman 2020). This is a long story that others have addressed, so I won't go into it here. 

A  review and meta-analysis of randomized controlled trials finds that "There is no robust evidence to support the use of the BCG vaccine for the treatment" of type 1 diabetes, "although the HbA1c levels tended to improve." (Chang et al. 2020). A systematic review and meta-analysis of studies found that the BCG vaccine did not affect the risk of type 1 diabetes (Jamshidi et al. 2023).

HPV Vaccines

The HPV vaccine Gardasil did not increase the risk of type 1 diabetes, or any of the other 15 autoimmune conditions analyzed (Chao et al. 2012). Additional reviews also found that the HPV vaccine did not increase the risk of type 1 diabetes or other autoimmune conditions (Grimaldi-Bensouda et al. 2017; Willame et al. 2019). A large, long-term California study found HPV did not increase the risk of type 1, even in the full 10 years following vaccination (Klein et al. 2019). 

COVID-19 Vaccines

Considering a large percentage of people throughout the world have recently gotten vaccinated for COVID-19, it's not surprising that a few of them developed diabetes after taking the vaccine (they might have developed it even without the vaccine, who knows). Note that getting COVID-19 itself also increases the risk of developing diabetes, at a much higher rate than taking the vaccine might (see the Viruses page for info on that topic). In fact, there is a lower risk of being diagnosed with diabetes following COVID in people unvaccinated as compared to people vaccinated (Kwan et al. 2023). In the U.S., vaccinated people had a 21% lower risk of developing new-onset diabetes than unvaccinated people (Hsieh et al. 2023). The incident rate of diabetes is lower after vaccination than before vaccination in Germany (Kowall et al. 2023). Similarly in Hong Kong, there was no evidence that the COVID vaccine increased the risk of diabetes, but there was evidence that the infection itself did increase risk (Xiong et al. 2023). That said, there are a few published case studies about people getting the COVID-19 vaccine and subsequent type 1 diabetes or diabetic ketoacidosis-- I'm not sure why but most of these case studies are from Japan; note also some of these people were also taking other drugs at the time of vaccination that are linked to diabetes development (Aydoğan et al. 2022; Bleve et al. 2022; Huang et al. 2023; Izumi et al. 2023; Kobayashi et al. 2022; Kshetree et al. 2022; Lin et al. 2022; Makiguchi et al. 2022; Moon et al. 2023; Ohuchi et al. 2022; Sakurai et al. 2022; Sasaki et al. 2022a; Sasaki et al. 2022b; Sato et al. 2022; Tang et al. 2022; Yano et al. 2022). But in general, on a large scale, for example in this study of over 14 million people, the COVID-19 vaccine did not increase the risk of type 1 diabetes (Liu et al. 2023). A review of the case reports finds that there have been a small number of new-onset diabetes cases coincidentally after the vaccine, the overall benefit outweighs that risk (Alsudais et al. 2023). 

For those who have diabetes, the COVID-19 vaccine is linked to a lower risk of hospitalization and death (the more doses the better), especially in people with type 1 (Heald et al. 2022). The large UK Biobank study found that COVID vaccines were associated with a reduced risk of hospitalization from a variety of diseases, including type 2 diabetes (Xiang et al. 2024). Vaccine response is better in people with more time in range the two weeks prior to vaccination (Alhamar et al. 2023), since people with diabetes in general may have a lower antibody response to the vaccine than the general population (He et al. 2023). The vaccine affects glucose control in people with diabetes only a small, statistically insignificant amount, according to a systematic review and meta-analysis (Lamichhane et al. 2024).

Get vaccinated people! Protect yourself, protect your family, protect those who can't get vaccinated-- like children with cancer. Please!

Vaccines and The Honeymoon Period

After type 1 diabetes diagnosis, many people have a "honeymoon period" of residual beta cell function that leads to better blood glucose control (also called "partial remission"). One study from Turkey found that children who were vaccinated for measles had a higher risk of having a honeymoon period after diagnosis (Bektaş et al. 2020).

Diabetes and Response to Vaccines

Does having type 1 diabetes affect people's response to vaccines? Perhaps. A study from Italy found that the hepatitis B vaccine was less effective in children with type 1 diabetes, but that a booster shot did help increase its effectiveness (Silvestri et al. 2019). 

Other things can also affect the response to vaccines, for example: environmental chemicals...

Vaccines and Environmental Chemicals

Note that the presence of environmental chemicals in the body may affect the efficacy of vaccines (e.g., Grandjean et al. 2017). Infants with higher levels of persistent organic pollutants in their bodies (PCBs and DDE) had lower levels of antibody response to the BCG vaccine (Jusko et al. 2016). Children exposed to mercury (as well as malnutrition) also have a lower antibody response to vaccines (Wyatt et al. 2019). Infants exposed to phthalates also have a different response to vaccines (Yang et al. 2019). Early life phthalate exposure also appears to lower antibody response to vaccines in children into the teenaged years (Wen et al. 2020).

Vaccines are one instance where the presence of potentially toxic chemicals are sometimes included by design, not by accident. The vaccine preservative thimerosal, for example, contains the heavy metal mercury. The effect of thimerosal on the immune system is largely unknown (Havarinasab et al. 2005). A few Swedish researchers have tried to elucidate these effects in animal studies. One study showed, for example, that thimerosal exposure in mice was associated with the development of autoantibodies, and accelerated disease, at doses similar to those in infant vaccines (Havarinasab and Hultman 2006). Another found that thimerosal treatment of genetically susceptible mice leads first to an immunosuppression stage, followed by a second phase of immunostimulation and autoimmunity (Havarinasab et al. 2005). Thimerosal was removed from most childhood vaccines in 2001 in the U.S., but sometimes remains in some as an adjuvant, such as some flu shots, although it is being removed from those as well.

Aluminum has also been used in vaccines as an adjuvant, but at such small levels that the amount of aluminum in the bodies of people who are vaccinated vs unvaccinated is the same. Studies have found no link between aluminum and autoimmunity either (Goullé and Grangeot-Keros, 2019), and numerous studies have found "minimal" adverse effects (Corkins et al. 2019). The large study of regular childhood vaccines mentioned above found that those with higher aluminum exposure from vaccines actually had a lower risk of type 1 diabetes (Glanz et al. 2021).

Flu Shots

A Swedish study found that the H1N1 flu (swine flu) vaccine may affect the development of type 1 diabetes in young children, although exactly how is a bit unclear. The levels of some autoantibodies associated with type 1 diabetes were higher during and after the vaccine was administered, but the proportion of young children with a certain genetic risk diagnosed with type 1 diabetes decreased after vaccination. The authors state, "it cannot be excluded that the vaccine affected clinical onset of type 1 diabetes" and that, "it can therefore not be excluded that the vaccination campaign may have delayed the clinical onset in young high-risk children but induced an earlier diagnosis in others" (Svensson et al. 2014).

A study of the H1N1 vaccine and autoimmune disease did not find a different between those given shots with adjuvant and without. Rates of type 1 and other autoimmune diseases were also not different than background rates would predict (Isai et al. 2012). Another study of the H1N1 vaccine also found no increased risk of type 1 diabetes (Bardage et al. 2011).

There was some debate about a Swedish study of the swine flu vaccine Pandemrix used in 2009-2010 (e.g., Andersson 2014; Persson 2015; Persson et al. 2017). A bunch of these letters have since been retracted, it seems. The original study found no increased risk of type 1 diabetes from this vaccine (Persson et al. 2014). A reanalysis that found different conclusion was retracted (Andersson 2017). As a follow-up, a large population-wide study from Norway with 4 years of follow up found no increased risk of Pandemrix and type 1 diabetes (Ruiz et al. 2018). An international study also found no increased risk of autoimmunity or type 1 diabetes-- in fact, in Finland, it found a decreased risk of autoimmunity and type 1 was associated with this vaccine (Elding Larsson et al. 2018).

Interestingly, the Pandemerix vaccine may have affected the efficacy of a diabetes-prevention intervention trial using the GAD-alum vaccine. It appears the GAD-alum vaccine was more effective in preserving beta cell function in people newly diagnosed with type 1 diabetes who did not have the Pandemerix vaccine (Tavira et al. 2017).

The flu vaccine during pregnancy is not associated with an increased risk of gestational diabetes, and may help protect mother and baby (Mohammed et al. 2020).


To see or download the references cited on this page, see the collection Vaccines and diabetes/obesity in PubMed.